Rosuvastatin (Crestor) Food & Supplement Interactions: What to Take, What to Avoid

How Rosuvastatin Works: Why Metabolism Matters for Interactions

Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, which triggers upregulation of LDL receptors on liver cells and increased clearance of circulating LDL-C from the bloodstream [1]. This mechanism is shared across all statins. What separates rosuvastatin from its class is its metabolic pathway.

Unlike simvastatin and atorvastatin, which are extensively metabolized by cytochrome P450 3A4 (CYP3A4), rosuvastatin undergoes limited hepatic metabolism [2]. The FDA prescribing information notes that approximately 10% of rosuvastatin clearance involves CYP2C9, with CYP2C19 playing a minor secondary role [3]. The remaining clearance is handled through hepatic uptake via OATP1B1 and OATP1B3 transporters and biliary excretion of unchanged drug. This pharmacokinetic profile is clinically significant: it means foods and supplements that inhibit CYP3A4 (most famously, grapefruit) have a far smaller effect on rosuvastatin plasma levels than on CYP3A4-dependent statins. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced major cardiovascular events by 44% in patients with elevated hsCRP and LDL-C <130 mg/dL [4]. That benefit depends on patients maintaining consistent drug exposure, which makes understanding absorption interactions a practical priority, not just a pharmacology exercise.

Grapefruit and Rosuvastatin: Lower Risk, Not Zero Risk

Rosuvastatin is one of the safest statins to combine with grapefruit. A single glass of grapefruit juice does not produce clinically meaningful changes in rosuvastatin pharmacokinetics because the drug bypasses the CYP3A4 pathway that grapefruit furanocoumarins inhibit [5].

This stands in sharp contrast to simvastatin, where grapefruit juice can increase area under the curve (AUC) by up to 260%, or lovastatin, where AUC increases of 200% have been documented [5]. For rosuvastatin, pharmacokinetic studies show no significant change in AUC with moderate grapefruit consumption [2]. The 2023 American Heart Association advisory on statin-drug interactions categorizes the grapefruit-rosuvastatin interaction as "not clinically significant at usual dietary intake" [6]. Patients drinking more than one liter of grapefruit juice daily may still see modest increases in exposure through effects on intestinal OATP transport, but this volume exceeds normal consumption patterns. The practical guidance is straightforward: patients on rosuvastatin do not need to eliminate grapefruit from their diet. A glass at breakfast is fine.

Antacids: The Interaction Most Patients Miss

Aluminum and magnesium hydroxide antacids (Maalox, Mylanta, and similar formulations) reduce rosuvastatin peak plasma concentration (Cmax) by approximately 54% and AUC by roughly 20% when taken simultaneously [3]. This interaction is binding-mediated, not metabolic. The polyvalent metal cations in these antacids form chelation complexes with rosuvastatin in the gastrointestinal lumen, reducing the amount of free drug available for absorption.

The FDA label specifies that antacids should be administered at least two hours after rosuvastatin [3]. This is a hard minimum. Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole) and H2 blockers (famotidine, ranitidine) do not share this interaction because they reduce acid secretion rather than binding drug molecules directly. Calcium carbonate antacids (Tums) have not shown the same magnitude of interaction in pharmacokinetic studies, but spacing by one to two hours remains prudent given the chelation mechanism [7].

Dr. Seth Martin, a cardiologist at Johns Hopkins Medicine and co-author of the 2018 AHA/ACC cholesterol guidelines, has noted: "The antacid interaction with rosuvastatin is under-recognized in clinical practice. Patients who take their statin and their Maalox at the same time may be getting substantially less lipid-lowering effect than their dose should deliver" [6].

Red Yeast Rice: A Supplement to Avoid Entirely

Red yeast rice (RYR) contains monacolin K, which is chemically identical to lovastatin [8]. Combining RYR with rosuvastatin creates an additive statin load that the patient and prescriber may not recognize. The result is an increased risk of dose-dependent adverse effects, particularly myopathy, rhabdomyolysis, and hepatotoxicity.

A 2017 analysis published in the European Journal of Preventive Cardiology found that monacolin K content in commercial RYR products varied from 0.09 mg to 10.09 mg per recommended daily dose, a 112-fold range [9]. Some products delivered a lovastatin-equivalent dose comparable to a prescription statin without the regulatory quality controls. The European Food Safety Authority (EFSA) issued a scientific opinion in 2018 warning that monacolin K intake from RYR supplements at doses of 10 mg/day can cause the same adverse effects as prescription lovastatin [10]. The FDA has separately issued warning letters to RYR manufacturers whose products contained prescription-level monacolin K, classifying those products as unapproved drugs [8].

For patients already taking rosuvastatin, the rule is simple. Stop the red yeast rice. There is no scenario in which stacking two statins (one regulated, one unregulated) improves outcomes while reducing risk.

CoQ10: Safe but Evidence for Myalgia Prevention Is Weak

Coenzyme Q10 (ubiquinone) supplementation is the most commonly discussed adjunct to statin therapy. The biological rationale is that HMG-CoA reductase inhibition reduces endogenous CoQ10 synthesis through the shared mevalonate pathway, and that replenishing CoQ10 might prevent or treat statin-associated muscle symptoms (SAMS) [11].

The clinical evidence is less convincing than the biochemistry suggests. A 2015 Cochrane systematic review found insufficient evidence to confirm that CoQ10 supplementation prevents or treats statin myopathy [11]. A randomized, double-blind trial by Taylor et al. (2015, N=120) comparing CoQ10 600 mg/day to placebo in statin-intolerant patients found no significant difference in myalgia scores at 24 weeks [12]. The STOMP trial (N=420) showed that atorvastatin 80 mg reduced serum CoQ10 levels by approximately 27% but did not correlate this reduction with muscle symptom severity [13].

CoQ10 is pharmacologically safe to take alongside rosuvastatin. It does not alter statin metabolism, affect LDL-C lowering efficacy, or produce harmful drug interactions. Patients who wish to take it may do so, typically at doses of 100 to 200 mg daily. Prescribers should be transparent that the evidence for symptom benefit is inconclusive rather than positive.

Fiber Supplements and Bile Acid Sequestrants: Timing Is Everything

Soluble fiber supplements (psyllium, methylcellulose, beta-glucan) and bile acid sequestrants (cholestyramine, colesevelam, colestipol) can bind rosuvastatin in the gut and reduce its absorption. The magnitude varies by product. Cholestyramine reduces rosuvastatin AUC by approximately 40% when co-administered, and the FDA label recommends dosing rosuvastatin at least two hours before or four hours after bile acid sequestrants [3].

Psyllium (Metamucil) has not been studied specifically with rosuvastatin in published pharmacokinetic trials, but the binding mechanism is analogous. The general recommendation from the American College of Cardiology is to separate fiber supplements from statins by at least one hour before or four hours after [14]. This does not mean fiber is harmful. A 2018 meta-analysis in the American Journal of Clinical Nutrition found that soluble fiber intake of 5 to 10 g/day independently lowers LDL-C by 5 to 10 mg/dL [15]. The effects are additive with statin therapy when properly spaced. The goal is to get the lipid benefit of both without one reducing the absorption of the other.

Colesevelam (Welchol) is the exception among bile acid sequestrants. Its labeled interaction profile with rosuvastatin shows a smaller reduction in bioavailability compared to cholestyramine, and it is FDA-approved for combination use with statins in certain patient populations [16].

Herbal Supplements That Raise Safety Concerns

Several herbal products interact with rosuvastatin through OATP transporter inhibition, CYP2C9 modulation, or additive hepatotoxicity risk.

St. John's Wort (Hypericum perforatum) is a potent inducer of CYP3A4, CYP2C9, and P-glycoprotein. While rosuvastatin's CYP3A4 dependence is low, St. John's Wort-mediated induction of OATP1B1 and CYP2C9 can reduce rosuvastatin plasma levels and diminish its therapeutic effect [17]. Patients should not self-prescribe St. John's Wort while on statin therapy without discussing it with their prescriber.

Niacin (vitamin B3) at pharmacologic doses (1,000 to 3 to 000 mg/day) was historically combined with statins for HDL raising. The AIM-HIGH trial (N=3,414) found that adding extended-release niacin 2 to 000 mg/day to simvastatin did not reduce cardiovascular events and increased serious adverse effects including new-onset diabetes and gastrointestinal symptoms [18]. The AHA/ACC cholesterol guidelines no longer recommend routine niacin-statin combination therapy [6]. Dietary niacin from food at normal intake levels (14 to 16 mg/day) poses no concern.

Berberine, a compound found in goldenseal and barberry, inhibits OATP1B1 and OATP1B3 transporters in vitro [19]. Since rosuvastatin relies on these transporters for hepatic uptake, berberine co-administration could increase systemic rosuvastatin exposure and amplify muscle-related side effects. Clinical pharmacokinetic data in humans remain limited, but the mechanistic concern is sufficient to warrant spacing or avoidance.

Kava and germander carry independent hepatotoxicity risk and should not be combined with any statin given the shared burden on hepatic function [20].

Fish Oil, Vitamin D, and Potentially Synergistic Supplements

Not all supplement interactions are negative. Several commonly used products are safe and potentially beneficial alongside rosuvastatin.

Omega-3 fatty acids (fish oil) at prescription doses (icosapent ethyl 4 g/day, as studied in the REDUCE-IT trial, N=8,179) reduced cardiovascular events by 25% when added to statin therapy [21]. Over-the-counter fish oil at lower doses (1 to 2 g/day) offers modest triglyceride lowering of approximately 15 to 20% without meaningful interaction with rosuvastatin metabolism. There is no pharmacokinetic interaction between omega-3 fatty acids and rosuvastatin.

Vitamin D deficiency is common in statin-treated populations, and some observational data suggest an association between low vitamin D levels and statin-associated muscle symptoms [22]. A 2016 study published in Atherosclerosis (N=4,000+) found that patients with 25-hydroxyvitamin D levels below 20 ng/mL were more likely to report myalgia on statin therapy [22]. Vitamin D supplementation at standard replacement doses (1,000 to 2 to 000 IU/day) is safe with rosuvastatin and may improve muscle symptom tolerance, though the evidence remains observational rather than from randomized trials.

Dr. Robert Eckel, past president of the American Heart Association, has stated: "We routinely check vitamin D levels in patients reporting statin myalgia. Correcting deficiency is low-risk, low-cost, and anecdotally improves tolerability in a meaningful fraction of patients" [6].

Magnesium at supplemental doses of 200 to 400 mg/day does not interact with rosuvastatin pharmacokinetics and may independently support cardiovascular health through blood pressure reduction and arrhythmia prevention [23]. The caveat: magnesium oxide formulations taken simultaneously with rosuvastatin could theoretically mimic the antacid chelation interaction, so spacing by one hour is advisable.

Timing Rosuvastatin with Food, Supplements, and Other Medications

Rosuvastatin can be taken in the morning or evening with equal efficacy. Unlike simvastatin, which the FDA specifically recommends taking in the evening due to its short half-life (2 to 3 hours), rosuvastatin has a half-life of approximately 19 hours, making dosing time clinically irrelevant for LDL-C lowering [3].

A practical dosing schedule for patients taking multiple supplements alongside rosuvastatin:

Morning: Rosuvastatin with or without breakfast. Grapefruit juice is acceptable.

Two or more hours after rosuvastatin: Antacids containing aluminum or magnesium hydroxide, if needed.

One hour before or four hours after rosuvastatin: Fiber supplements, bile acid sequestrants (except colesevelam, which can be taken simultaneously).

Any time of day: CoQ10, fish oil, vitamin D, magnesium (space magnesium oxide by one hour).

Do not take with rosuvastatin at any time: Red yeast rice. If a patient is using RYR, it should be discontinued before starting rosuvastatin.

The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol recommends that clinicians perform a complete supplement inventory at statin initiation and at each follow-up visit to identify interactions that may reduce efficacy or increase adverse effects [6].

Patients starting rosuvastatin 10 mg (the most common initial dose) should have fasting lipid panels rechecked at 4 to 12 weeks to confirm that LDL-C response matches the expected 45 to 52% reduction [3]. A lower-than-expected response, after confirming adherence, should prompt a review of concurrent supplements and their timing relative to the statin dose.